Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             171 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abnormal expression of calpain-6 due to endothelin-1/NFκB signalling contributes to cell survival and chemoresistance in osteosarcoma cells Marion*, A.
 2011
 48 1 p. S38-
1 p.
 artikel
2 Accelerated osteolytic metastasis in B16-inoculated mice pre-exposed to non-skeletal focal irradiation in the abdomen Fu, Q.
 2011
 48 1 p. S38-S39
2 p.
 artikel
3 Activation of the osteopontin gene, a bone metastatic signature, by transcription factor ERG in prostatic cancer cells Flajollet, S.
 2011
 48 1 p. S33-
1 p.
 artikel
4 A direct contact model system to study tumor cell–bone cell interactions in prostate cancer bone metastases Nordstrand*, A.
 2011
 48 1 p. S40-
1 p.
 artikel
5 Adjuvant effect of IV clodronate on delay of bone metastasis in high-risk prostate cancer patients Rodrigues⁎ , P.
 2011
 48 1 p. S22-
1 p.
 artikel
6 Advances in management of bone disease in breast cancer Walkington, L.
 2011
 48 1 p. 80-87
8 p.
 artikel
7 Advances in the biology of bone metastasis: How the skeleton affects tumor behavior Sterling, Julie A.
 2011
 48 1 p. 6-15
10 p.
 artikel
8 A method to follow tumor growth and tumor induced bone loss simultaneously over time, in vivo, using whole body bioluminescence fluorescence imaging Snoeks*, T.J.A.
 2011
 48 1 p. S49-S50
2 p.
 artikel
9 A multicenter prospective study of the risk factors affecting bone mineral density in Korean patients with prostate cancer Jung, S.I.
 2011
 48 1 p. S23-
1 p.
 artikel
10 Analysis of the various components of bone turnover in postmenopausal breast cancer patients with bone metastases Bertoldo*, F.
 2011
 48 1 p. S30-
1 p.
 artikel
11 A new Β Crosslaps® (CTX-I) assay on the IDS-ISYS automated analyser Seres*, Z.
 2011
 48 1 p. S47-
1 p.
 artikel
12 An exopolysaccharide produced by alteromonas infernus reduces lung metastasis and prolongs survival rate of osteosarcoma-bearing mice Ruiz Velasco*, C.
 2011
 48 1 p. S42-S43
2 p.
 artikel
13 An observational prospective cohort study on the dose effect of zoledronic acid on urinary n-telopeptide levels in metastatic prostate cancer Drudge-Coates*, L.
 2011
 48 1 p. S22-S23
2 p.
 artikel
14 A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease Aklilu*, M.
 2011
 48 1 p. S17-
1 p.
 artikel
15 Artificial niches that direct stem cell fate Lutolf, M.P.
 2011
 48 1 p. S5-
1 p.
 artikel
16 A study of the role of twist in migration and invasion of breast cancer cells Li, S.
 2011
 48 1 p. S33-S34
2 p.
 artikel
17 Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class Clézardin, Philippe
 2011
 48 1 p. 71-79
9 p.
 artikel
18 BMP2/7 heterodimeric proteins are potent antagonists of TGFbeta-induced signaling, invasiveness and bone metastasis via inhibition of cancer stem cells Buijs, J.T.
 2011
 48 1 p. S15-S16
2 p.
 artikel
19 Bone health in breast cancer survivors following adjuvant bisphosphonate therapy: AZURE quantitative bone scan sub-study Woodward*, E.J.
 2011
 48 1 p. S29-
1 p.
 artikel
20 Bone marrow endothelial cells as active players in the pathobiology of multiple myeloma Vanderkerken, K.
 2011
 48 1 p. S7-S8
2 p.
 artikel
21 Bone mineral density and bone remodelling markers osteocalcin and alkaline phosphatase in patients with Stage IV breast cancer Lumachi*, F.
 2011
 48 1 p. S27-
1 p.
 artikel
22 Breast cancer cell epidermal growth factor receptor signaling and osteolysis Nickerson*, N.K.
 2011
 48 1 p. S51-S52
2 p.
 artikel
23 Breast carcinoma cells modulate main characteristics and functional properties of human bone marrow-derived mesenchymal stromal cells in a non-contact dependent manner Wobus*, M.
 2011
 48 1 p. S52-
1 p.
 artikel
24 Calcium metabolism in castration-resistant prostate cancer patients: Development of a quantitative urinary assay for extent of bone metastasis Hillegonds*, D.J.
 2011
 48 1 p. S54-
1 p.
 artikel
25 Camp-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction Son, J.
 2011
 48 1 p. S34-
1 p.
 artikel
26 Can bone biopsies be used to confirm metastatic disease recurrence and receptor status in breast cancer patients? Amir*, E.
 2011
 48 1 p. S27-
1 p.
 artikel
27 Cancer and the evolution of stem cell fates Andrews, P.W.
 2011
 48 1 p. S6-
1 p.
 artikel
28 Cathepsin K inhibitors for the treatment of bone metastasis Lindström*, E.
 2011
 48 1 p. S51-
1 p.
 artikel
29 CCN3 impairs osteoblasts and stimulates osteoclast differentiation to favor breast cancer metastasis to bone Amir*, E.
 2011
 48 1 p. S32-S33
2 p.
 artikel
30 Cell trafficking in multiple myeloma Ghobrial, I.
 2011
 48 1 p. S8-
1 p.
 artikel
31 Challenges of research on circulating tumour cells in carcinoma patients Riethdorf, S.
 2011
 48 1 p. S9-
1 p.
 artikel
32 Changes in osteoblast and osteoclast number rely on direct contact with breast cancer cells — Evidence from a longitudinal study of bone metastasis Brown*, H.K.
 2011
 48 1 p. S40-S41
2 p.
 artikel
33 Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis Lipton, Allan
 2011
 48 1 p. 96-99
4 p.
 artikel
34 Combination vs single agent treatment: The effects of zoledronic acid+/−doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease Brown*, H.K.
 2011
 48 1 p. S41-
1 p.
 artikel
35 Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population Wu*, E.Q.
 2011
 48 1 p. S31-
1 p.
 artikel
36 Comparison of optical, radiography and micro-Computed Tomography imaging methods for the analysis of bone metastases in a murine model Tiwari*, S.
 2011
 48 1 p. S40-
1 p.
 artikel
37 Controlled skeletal tissue ablation using novel navigational radio frequence ablation device Kurth*, A.A.
 2011
 48 1 p. S36-
1 p.
 artikel
38 Controversies in the use of bone targeted agents: Breast cancer prevention Chlebowski, R.T.
 2011
 48 1 p. S6-S7
2 p.
 artikel
39 Corning osteo assay surface for the study of bone resorption Faruqi*, A.F.
 2011
 48 1 p. S47-
1 p.
 artikel
40 CpG-ODN inhibits Smad-dependent BMP signaling; Effects on myeloma cell apoptosis and in vitro osteoblastogenesis Nørgaard, N.
 2011
 48 1 p. S41-S42
2 p.
 artikel
41 Denosumab decreases proliferation in giant cell tumor of bone (GCTB) Roudier, M.
 2011
 48 1 p. S15-
1 p.
 artikel
42 Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: Results from a phase 3 randomized trial Brown*, J.
 2011
 48 1 p. S16-
1 p.
 artikel
43 Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials Lipton*, A.
 2011
 48 1 p. S21-
1 p.
 artikel
44 Development of a targeted strategy for enrichment and detection of calcium-binding proteins as potential biomarkers for bone metastases in breast cancer Wood*, S.L.
 2011
 48 1 p. S50-S51
2 p.
 artikel
45 Direct anti-cancer effect of oncostatin M on chondrosarcoma David, E.
 2011
 48 1 p. S36-
1 p.
 artikel
46 Does differential expression of CD151 affect the ability of beast cancer cells to establish tumours in bone? Wind*, N.S.
 2011
 48 1 p. S45-
1 p.
 artikel
47 Dysregulation of developmental pathways in bone metastasis Sethi, Nilay
 2011
 48 1 p. 16-22
7 p.
 artikel
48 Editorial Board 2011
 48 1 p. i-ii
nvt p.
 artikel
49 Effect of VEGF inhibitor PF-00337219 and FAK/PYK2 inhibitor PF-562,271 on intratibial growth of breast cancer cells in nude rats and mice Bagi*, C.M.
 2011
 48 1 p. S54-
1 p.
 artikel
50 Effects of the bone marrow microenvironment on hematopoietic malignancy Askmyr, Maria
 2011
 48 1 p. 115-120
6 p.
 artikel
51 Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone Santini*, D.
 2011
 48 1 p. S23-S24
2 p.
 artikel
52 Epithelial plasticity, cancer stem cells and bone metastasis formation van der Pluijm, Gabri
 2011
 48 1 p. 37-43
7 p.
 artikel
53 Evaluation of a novel bone targeted aracytidine therapy in dogs with spontaneous osteosarcoma Zinnen*, S.
 2011
 48 1 p. S51-
1 p.
 artikel
54 Examination of the mechanism(s) of cancer-induced bone pain in animal models Ungard*, R.
 2011
 48 1 p. S39-
1 p.
 artikel
55 Experimental study of specific antitumor immunity induced by dendritic cell vaccine transfected with tumor cell total RNA in Ewing's sarcoma patients Sang*, H.X.
 2011
 48 1 p. S25-
1 p.
 artikel
56 Exploiting the tear proteome for the diagnosis of breast cancer Washam, C.
 2011
 48 1 p. S26-
1 p.
 artikel
57 Expression of matrix metalloproteinase 1 (MMP1) and dickkopf-1 (DKK1) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors Costa, L.
 2011
 48 1 p. S25-S26
2 p.
 artikel
58 First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model Ottewell*, P.D.
 2011
 48 1 p. S42-
1 p.
 artikel
59 First randomized trial comparing balloon kyphoplasty (BKP) to non-surgical management among cancer patients with vertebral compression fractures Bastian*, L.
 2011
 48 1 p. S20-
1 p.
 artikel
60 Foreword: Skeletal Complications of Cancer Smith, Matthew R.
 2011
 48 1 p. 5-
1 p.
 artikel
61 Gene expression in prostate cancer bone metastases in relation to expression of the androgen receptor and one of its constitutively active variants Hörnberg*, E.
 2011
 48 1 p. S29-S30
2 p.
 artikel
62 GLPG0187 inhibits progression of established bone metastasis and achieves maximum efficacy when combined with standard-of-care metastatic breast cancer treatments Clément-Lacroix, P.
 2011
 48 1 p. S45-
1 p.
 artikel
63 Glutamate release in bone metastasis Seidlitz*, E.P.
 2011
 48 1 p. S32-
1 p.
 artikel
64 Halofuginone reduces bone metastases: TGF-β-dependent and independent effects Juarez*, P.
 2011
 48 1 p. S19-S20
2 p.
 artikel
65 High-dose antioxidants as potential anti-osteolytic and palliative therapies for breast cancer bone metastasis Pfister, W.
 2011
 48 1 p. S53-
1 p.
 artikel
66 Human bone marrow-derived mesenchymal stem cell homing to orthotopic breast cancer tumors and promotion of bone metastasis Reagan*, M.R.
 2011
 48 1 p. S13-
1 p.
 artikel
67 Hypocalcemia in multiple myeloma secondary to unrecognised vitamin D deficiency: A case report Ramasamy*, I.
 2011
 48 1 p. S27-S28
2 p.
 artikel
68 IBMS 2011 Corporate Partners 2011
 48 1 p. 2-
1 p.
 artikel
69 IBMS Elected Board of Directors 2010–2011 2011
 48 1 p. 1-
1 p.
 artikel
70 IBMS Membership Application 2011
 48 1 p. 3-
1 p.
 artikel
71 Identification of hydrogen sulfide releasing compounds as novel antiresorptive and antitumour agents Idris*, A.I.
 2011
 48 1 p. S44-
1 p.
 artikel
72 Identification of plasma biomarkers that predict breast cancer bone metastasis Washam*, C.L.
 2011
 48 1 p. S13-S14
2 p.
 artikel
73 Immune interplay between osteolytic disease and bone metastasis Monteiro, A.C.
 2011
 48 1 p. S54-S55
2 p.
 artikel
74 Improved methods for 3D SEM imaging of cancellous bone in metastatic cancers in bone Boyde*, A.
 2011
 48 1 p. S53-
1 p.
 artikel
75 Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma Brown*, J.E.
 2011
 48 1 p. S18-S19
2 p.
 artikel
76 Influence of pre-treatment with bisphosphonate on the outcome of photodynamic therapy on breast cancer metastases in murine vertebrae Akens*, M.K.
 2011
 48 1 p. S35-S36
2 p.
 artikel
77 Inhibition of Dickkopf-1 (DKK-1) delays prostate cancer growth in vivo through induction of P21CIP-1 Hall*, C.L.
 2011
 48 1 p. S43-S44
2 p.
 artikel
78 Inhibition of discoidin domain receptor-1 (DDR1) impairs tumor-induced osteoclastogenesis preventing bone metastatic homing and colonization Valencia*, K.
 2011
 48 1 p. S48-S49
2 p.
 artikel
79 Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions Schneider, Jochen G.
 2011
 48 1 p. 54-65
12 p.
 artikel
80 Interaction of autotaxin with breast cancer cell integrins might contribute to lysophosphatidic acid-mediated bone metastases David, M.
 2011
 48 1 p. S39-S40
2 p.
 artikel
81 Involvement of acidic microenvironment in bone pain associated with cancer colonization Yoneda, T.
 2011
 48 1 p. S11-
1 p.
 artikel
82 Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain Yoneda, Toshiyuki
 2011
 48 1 p. 100-105
6 p.
 artikel
83 Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease Buckle*, C.
 2011
 48 1 p. S19-
1 p.
 artikel
84 Lessons to be learned from osteosarcoma Heymann, D.
 2011
 48 1 p. S11-
1 p.
 artikel
85 Local treatment of mixed osteolytic/osteoblastic spinal metastases: Is photodynamic therapy effective? Wise-Milestone*, L.
 2011
 48 1 p. S35-
1 p.
 artikel
86 Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction Johnson, Lindsay C.
 2011
 48 1 p. 141-151
11 p.
 artikel
87 Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis Lynch, Conor C.
 2011
 48 1 p. 44-53
10 p.
 artikel
88 Mechanisms of osteoblast supression in multiple myeolma Kassen*, D.
 2011
 48 1 p. S37-
1 p.
 artikel
89 Metastatic bone disease of the mandible — A case report Drozdzowska*, B.
 2011
 48 1 p. S28-S29
2 p.
 artikel
90 Metastatic bone disease: Role of transcription factors and future targets Pratap, Jitesh
 2011
 48 1 p. 30-36
7 p.
 artikel
91 MNNG-HOS osteosarcoma growth is enhanced by human fat and adipose-derived mesenchymal stem cells: Implication in reconstructive surgery following tumor treatment Bourdais, L.
 2011
 48 1 p. S43-
1 p.
 artikel
92 Modeling the metastatic microenvironment in bone — A single niche for hematopoietic stem cells and cancer provided by skeletal progenitors Bianco, P.
 2011
 48 1 p. S5-
1 p.
 artikel
93 Molecular beacon-guided surgical resection of primary spinal neoplasms Liu*, T.W.
 2011
 48 1 p. S52-
1 p.
 artikel
94 Molecular characterization of the stromal response to osteoblastic bone metastasis by tissue-compartment specific transcriptional profiling Ozdemir*, B.
 2011
 48 1 p. S41-
1 p.
 artikel
95 Molecular genetics and risk of metastasis Linn, S.C.
 2011
 48 1 p. S5-S6
2 p.
 artikel
96 62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer Gnant*, M.
 2011
 48 1 p. S17-
1 p.
 artikel
97 Multiphoton imaging of individual myeloma cells in calvariae: Association of myeloma development with sites of bone turnover Williams*, A.J.
 2011
 48 1 p. S14-
1 p.
 artikel
98 Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey Santini*, D.
 2011
 48 1 p. S23-
1 p.
 artikel
99 Neuroblastoma and bone metastases: Clinical significance and prognostic value of Dickkopf 1 plasma levels Granchi, Donatella
 2011
 48 1 p. 152-159
8 p.
 artikel
100 New anabolic approaches to treating myeloma bone disease Roodman, G.
 2011
 48 1 p. S9-
1 p.
 artikel
101 New therapies for cancer induced bone disease: Clinical perspective Van Poznak, C.
 2011
 48 1 p. S10-
1 p.
 artikel
102 New therapies for cancer-induced bone disease: Preclinical perspective Guise, T.
 2011
 48 1 p. S9-S10
2 p.
 artikel
103 [No title] 2011
 48 1 p. S52-
1 p.
 artikel
104 [No title] 2011
 48 1 p. S38-
1 p.
 artikel
105 [No title] 2011
 48 1 p. S51-
1 p.
 artikel
106 [No title] 2011
 48 1 p. S49-
1 p.
 artikel
107 [No title] 2011
 48 1 p. S54-
1 p.
 artikel
108 [No title] 2011
 48 1 p. S31-
1 p.
 artikel
109 [No title] 2011
 48 1 p. S51-
1 p.
 artikel
110 [No title] 2011
 48 1 p. S25-
1 p.
 artikel
111 [No title] 2011
 48 1 p. S31-
1 p.
 artikel
112 [No title] 2011
 48 1 p. S28-
1 p.
 artikel
113 [No title] 2011
 48 1 p. S33-
1 p.
 artikel
114 Novel application of aptamer selection (pheno-SELEX) to target the invasive phenotype successfully creates anti-metastatic aptamers Shelley*, G.
 2011
 48 1 p. S38-
1 p.
 artikel
115 One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study Singh*, S.
 2011
 48 1 p. S24-
1 p.
 artikel
116 Optical advances in skeletal imaging applied to bone metastases Snoeks, T.J.A.
 2011
 48 1 p. 106-114
9 p.
 artikel
117 Osteoblast function in myeloma Roodman, G. David
 2011
 48 1 p. 135-140
6 p.
 artikel
118 Osteoclast-dependent and -independent effects of RANKL inhibition on tumorigenesis and metastasis Dougall, B.
 2011
 48 1 p. S10-S11
2 p.
 artikel
119 Osteocyte-derived FGF23 activates EGR-1 signaling in prostate cancer cells: A new vicious cycle in bone metastases Fournier, P.
 2011
 48 1 p. S48-
1 p.
 artikel
120 Osteolytic versus mixed osteolytic/osteoblastic vertebral metastasis: Comparison of bone structural and remodelling properties in two preclinical rat models Wise-Milestone*, L.
 2011
 48 1 p. S35-
1 p.
 artikel
121 Osteoprotegerin inhibitits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL produced by tumor cells Picarda, G.
 2011
 48 1 p. S34-
1 p.
 artikel
122 Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefits from zoledronic acid Body*, J.
 2011
 48 1 p. S20-S21
2 p.
 artikel
123 Peripheral cannabinoid type 2 receptor regulates osteoclast formation, MDA-MB-231 breast cancer cell migration and bone marrow/tumour cell interaction via PI3 kinase/AKT and P38 pathways Sophocleous*, A.
 2011
 48 1 p. S44-
1 p.
 artikel
124 Probing the relationship between breast cancer stem cells and bone metastasis Tan-Allen, K.
 2011
 48 1 p. S46-
1 p.
 artikel
125 Prospective clinical trial to evaluate the value of radiofrequence ablation and cement augmentation of spinal metastases Proschek, D.
 2011
 48 1 p. S28-
1 p.
 artikel
126 Prostate cancer-derived exosomes down-modulate NKG2D expression in immune effector cells Lundholm*, M.
 2011
 48 1 p. S53-
1 p.
 artikel
127 Quiescent stem cells in intestinal homeostasis, inflammation, and cancer Fodde, R.
 2011
 48 1 p. S6-
1 p.
 artikel
128 RANKL silencing by siRNA improves therapeutic response of primary osteosarcoma to conventional chemotherapy Rousseau, J.
 2011
 48 1 p. S34-S35
2 p.
 artikel
129 Rapid pain reduction following loading-dose ibandronate in bone metastases Kurth*, A.A.
 2011
 48 1 p. S28-
1 p.
 artikel
130 RAP-661 treatment, an ALK3 (BMPRIA) antagonist, decreases rankl and regulates osteoclastogenesis Solban*, N.
 2011
 48 1 p. S50-
1 p.
 artikel
131 Reactivation of EMT-inducing transcription factors and cancer development Puisieux, A.
 2011
 48 1 p. S4-S5
2 p.
 artikel
132 Reduced risk of breast cancer in postmenopausal women with osteoporosis. Preliminary results in a high risk metropolitan area: A case–control study Lumachi*, F.
 2011
 48 1 p. S26-
1 p.
 artikel
133 Relationship between serum N-telopeptide and bone alkaline phosphatase and their diagnostic value in patients with breast cancer and bone metastases Lumachi⁎, F.
 2011
 48 1 p. S25-
1 p.
 artikel
134 Results of the Medical Research Council (MRC) Myeloma IX study: Effects of zoledronic acid (ZOL) on overall survival (OS) in patients with multiple myeloma (MM) Morgan*, G.J.
 2011
 48 1 p. S16-S17
2 p.
 artikel
135 Risk of osteonecrosis of the jaw and the use of bone targeted therapies Ruggiero, S.L.
 2011
 48 1 p. S7-
1 p.
 artikel
136 Role of macrophages in tumour progression and therapy Lewis, C.E.
 2011
 48 1 p. S8-
1 p.
 artikel
137 Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE–BIG 01–04) for women with stage II/III breast cancer Coleman, R.E.
 2011
 48 1 p. S29-
1 p.
 artikel
138 Skeletal complications and survival in renal cancer patients with bone metastases Woodward, Emma
 2011
 48 1 p. 160-166
7 p.
 artikel
139 Skeletal rigidity enhances TGF-Β effects on cancer cell expression of osteolytic factors Ruppender, N.S.
 2011
 48 1 p. S39-
1 p.
 artikel
140 Spontaneous fusion between prostate cancer cells: A driver for development of tumor heterogeneity and growth in bone Pesce*, G.
 2011
 48 1 p. S46-S47
2 p.
 artikel
141 SRC inhibition as an approach to treating tumor-induced bone disease Boyce, B.F.
 2011
 48 1 p. S11-S12
2 p.
 artikel
142 Surgical resection of isolated breast cancer recurrence within the sternum Crighton*, J.
 2011
 48 1 p. S22-
1 p.
 artikel
143 Targeting cancer invasion and metastasis Frame, M.
 2011
 48 1 p. S8-S9
2 p.
 artikel
144 Targeting TCF transcriptional activity rescues syndecan-2 expression and re-sensitizes human osteosarcoma cells and mouse bone tumours to doxorubicin Dieudonné*, F.X.
 2011
 48 1 p. S37-S38
2 p.
 artikel
145 Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo Vitovski*, S.
 2011
 48 1 p. S15-
1 p.
 artikel
146 TGF-β in cancer and bone: Implications for treatment of bone metastases Juárez, Patricia
 2011
 48 1 p. 23-29
7 p.
 artikel
147 TGF-β promotion of GLI2 induced pthrp expression is independent of canonical hedgehog signaling Johnson*, R.W.
 2011
 48 1 p. S14-S15
2 p.
 artikel
148 TGF-β-related mechanisms of bone destruction in multiple myeloma Matsumoto, Toshio
 2011
 48 1 p. 129-134
6 p.
 artikel
149 TGFβ target gene NEDD9 identified by gene profiling plays a critical role in breast cancer bone metastasis Hata*, K.
 2011
 48 1 p. S13-
1 p.
 artikel
150 The addition of zoledronic acid to combination chemotherapy decreases circulating serum levels of vascular endothelial growth factor (VEGF) in early breast cancer Winter*, M.C.
 2011
 48 1 p. S30-S31
2 p.
 artikel
151 The bone remodeling environment is a factor in breast cancer bone metastasis Ooi, Li Laine
 2011
 48 1 p. 66-70
5 p.
 artikel
152 The causal role of the BMP signalling antagonist noggin in suppressing bone formation in osteolytic bone metastasis Secondini*, C.
 2011
 48 1 p. S42-
1 p.
 artikel
153 The chemokine receptor CXCR7 is highly expressed in bone metastatic lesions of human prostate cancer and mediates tumor cell growth and invasiveness in preclinical models Gravina, G.L.
 2011
 48 1 p. S32-
1 p.
 artikel
154 The homing of prostate cancer to bone in vivo is modulated by Zoledronic acid Reeves*, K.J.
 2011
 48 1 p. S45-S46
2 p.
 artikel
155 The Italian cross-sectional survey on the management of bone health in oncology: The ZETA study (On Behalf of ZETA Study Group) Bertoldo*, F.
 2011
 48 1 p. S24-
1 p.
 artikel
156 The novel and selective insulin-like growth factor-1 receptor kinase inhibitor PQIP suppresses bone cell function and osteoclast-breast cancer cell cross-talk in vitro Logan*, J.G.
 2011
 48 1 p. S43-
1 p.
 artikel
157 The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma Watanabe*, K.
 2011
 48 1 p. S36-S37
2 p.
 artikel
158 The role of fibronectin originating from different sources on breast cancer metastasis development and bone remodeling von Au, A.
 2011
 48 1 p. S50-
1 p.
 artikel
159 The role of macrophage stimulating protein in metastasis of breast cancer to bone Kretschmann*, K.
 2011
 48 1 p. S18-
1 p.
 artikel
160 The role of pamidronate in palliative treatment for bone metastases in squamous cell carcinoma of head and neck Rolski*, W.
 2011
 48 1 p. S31-
1 p.
 artikel
161 The role of parathyroid hormone-related protein in giant cell tumour of bone Cowan*, R.W.
 2011
 48 1 p. S48-
1 p.
 artikel
162 The search for metastatic founder cells: Molecular analysis of disseminated tumour cells from bone marrow of cancer patients Klein, C.A.
 2011
 48 1 p. S4-
1 p.
 artikel
163 10th International Conference on Cancer Induced Bone Disease 2011
 48 1 p. S3-
1 p.
 artikel
164 10th International Conference on Cancer Induced Bone Disease, 22–25 September 2010, Sheffield, UK Abstracts 2011
 48 1 p. S2-
1 p.
 artikel
165 TIMP-3 up-regulation facilitates osteoclastogenesis and suppresses DC differentiation from monocytes in the bone marrow microenvironment in myeloma Abe*, M.
 2011
 48 1 p. S18-
1 p.
 artikel
166 Towards biomarkers of bone-metastasis using cellular proteomics Westbrook*, J.A.
 2011
 48 1 p. S33-
1 p.
 artikel
167 Treatment and prevention of bone complications from prostate cancer Lee, Richard J.
 2011
 48 1 p. 88-95
8 p.
 artikel
168 Tumor–host cell interactions in the bone disease of myeloma Fowler, Jessica A.
 2011
 48 1 p. 121-128
8 p.
 artikel
169 Tumour-secreted lox mediates osteolytic bone metastases prior to metastatic tumour cell colonisation Evans, H.R.
 2011
 48 1 p. S21-
1 p.
 artikel
170 Twist 1 expression in an osteotropic breast cancer cell line promotes bone metastasis formation in mouse Croset*, M.
 2011
 48 1 p. S47-S48
2 p.
 artikel
171 Zoledronic acid induces IPP accumulation and release from human cancer cells, which activates Vγ9Vδ2 T cell-differentiation and migration in vitro and mediates Vγ9Vδ2 T cell-induced cancer cell death in vivo Benzaid*, I.
 2011
 48 1 p. S46-
1 p.
 artikel
                             171 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland